Edwin Jabbari

Parkinson’s disease (PD) is the commonest neurodegenerative cause of parkinsonism and, in terms of prevalence, is the fastest growing neurological disorder in the world. In the clinical setting, there are challenges in achieving an early and accurate diagnosis of PD due to clinical overlap with less common parkinsonian disorders, such as progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).

Parkinson’s disease (PD) is the commonest neurodegenerative cause of parkinsonism and, in terms of prevalence, is the fastest growing neurological disorder in the world. In the clinical setting, there are challenges in achieving an early and accurate diagnosis of PD due to clinical overlap with less common parkinsonian disorders, such as progressive supranuclear palsy (PSP), corticobobasal syndrome (CBS), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).

Abstract There are 90 independent genome-wide significant genetic risk variants for Parkinson’s disease (PD) but currently only five nominated loci for PD progression. The biology of PD progression is likely to be of central importance in defining mechanisms that can be used to develop new treatments.